LIVe 2022 -- There is a current push to investigate the toxicity of emerging Next Generation Products (NGPs) including Electronic Nicotine Delivery System (ENDS) and Heated Tobacco Product (HTP) products. 3D airway tissue models are a relevant method for analysis of toxicity for these aerosol products.
STP 2022 -- Sprague Dawley (SD) rats are commonly used in toxicologic pathology studies and frequently the rodent choice for two-year (104-week) carcinogenicity studies. It is important to accurately identify rare and common spontaneous neoplasms for proper assessment of the carcinogenic potential of the test article in such studies.
STP 2022 -- In an effort to better align the positioning of clinical pathology findings in reports and regulatory documents amongst the global clinical pathology toxicologic pathology community, this European Society of Toxicologic Pathology (ESTP) Working Group was formed to discuss the inconsistent utilization of terms such as "biological relevance" and
STP 2022 -- Sprague Dawley (SD) rats are commonly used in toxicologic pathology studies and frequently the rodent choice for two-year (104-week) carcinogenicity studies. It is important to accurately identify rare and common spontaneous neoplasms for proper assessment of the carcinogenic potential of the test article in such studies.
STP 2022 -- Historical control data are important tools used in toxicologic pathology for the evaluation and interpretation of neoplastic and nonneoplastic findings reported during rodent carcinogenicity studies.
Large clinical trials demand experience managing complex organizational requirements to synchronize many moving parts. In the past, Labcorp Drug Development has successfully conducted 14 global mega-trials involving cardiovascular outcomes.
CF remains one of the most common life-shortening inherited diseases, despite breakthroughs in targeted therapies in recent years. Research and development efforts continue, but those involved face major challenges in finding specialized trial sites and enrolling enough eligible patients.
Your drug candidate has potential to become the next medical breakthrough. When your studies need support in overcoming operational challenges, we can scale our customizable staffing service to best fit your needs and budget.
